The Cancer Letter

Inside information on cancer research and drug development

Drugs & Targets

Shasqi, Johnson & Johnson expand existing research collaboration

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Shasqi, Inc. and Johnson & Johnson Enterprise Innovation Inc. have expanded their ongoing research collaboration.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Moungi G. Bawendi, Louis E. Brus, Alexei I. Ekimov awarded 2023 Nobel Prize in Chemistry for quantum dots

Moungi Bawendi (left), Louis Brus (center) and Alexei Ekimov (right)Photo credit: Niklas Elmehed © Nobel Prize OutreachMoungi G. Bawendi, Louis E. Brus, and Alexei I. Ekimov were jointly awarded the 2023 Nobel Prize in Chemistry for their discovery and development of quantum dots—nanoparticles so tiny that their size determines their properties. These smallest components of nanotechnology now spread their light from televisions and LED lamps, and can also guide surgeons when they remove tumor tissue, among many other applications.
Drugs & Targets

Veeva and Merck form long-term strategic partnership

Veeva Systems formed a ten-year strategic partnership agreement with Merck, that builds on the existing 12-year partnership between the companies. Under the terms of the agreement, Merck will take a Veeva-first approach to new industry-specific software and data, selecting Veeva products when they are fit for purpose to maximize the value of Veeva’s integrated, cloud-based platform and products. 
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account